Table 3.
Data of Parallel Sequencing of Our Patient Cohort (n = 39)
| Other Mutated Genes | TP53 Wild Type n = 27 | TP53 Mutated n = 12 |
|---|---|---|
| No other mutated genes | 21 | 10 |
| BRAF | 0 | p.V600E activating (AF 40.5%)* |
| KRAS | p.G12D activating (AF 27.0%) |
p.G12D activating (AF 40.3%) |
| NRAS | 0 | 0 |
| HRAS | 0 | 0 |
| KEAP1 | 1 × p.V369A unknown (AF 35.7%) 2 × p.Q620del unknown (AF 27.6% | 27.2%) |
p.E343* activating (AF 36.1%)* |
| PIK3CA | p.E542K activating (AF 2.7%) |
0 |
| PTEN | 1 × p.R47S unknown (AF 14.3%) 1 × p.D24Gfs*20 truncated protein (AF 4.4%) |
0 |
| DDR2 | 0 | 0 |
| ERBB2 | 0 | 0 |
| NFE2L2 | 0 | 0 |
| RHOA | 0 | 0 |
AF, allele frequency.
*
Additional mutations in the same tumor.